79 results
PRE 14A
ELTX
Elicio Therapeutics, Inc.
17 Sep 24
Preliminary proxy
4:05pm
. Ruffolo served as an Executive Vice President at Wyeth Pharmaceuticals, where he was responsible for Pharmaceutical Research and Development. Prior … . Adams served as President of Research and Development at Infinity Pharmaceuticals, Inc. from 2003 to 2017, and also as its Chief Scientific Officer
8-K
EX-99.1
ELTX
Elicio Therapeutics, Inc.
13 Aug 24
Results of Operations and Financial Condition
4:33pm
2023 Operating expenses: Research and development $ 8,180 $ 4,944 General and administrative 2,744 2,833 Total operating expenses 10,924 7,777 Loss
424B5
ELTX
Elicio Therapeutics, Inc.
28 Jun 24
Prospectus supplement for primary offering
9:08pm
clinical trials, our research and development programs or other operations.
We have broad discretion in the use of the net proceeds from this offering … , progress and results of our research and development programs;
the timing, scope and likelihood of regulatory filings and approvals, including timing
424B5
ELTX
Elicio Therapeutics, Inc.
27 Jun 24
Prospectus supplement for primary offering
4:42pm
be forced to delay, reduce or eliminate certain of our clinical trials, our research and development programs or other operations.
We have broad … will become available, and the timing, progress and results of our research and development programs;
the timing, scope and likelihood of regulatory filings
8-K
EX-99.1
sisva9
27 Jun 24
Elicio Therapeutics Announces Preliminary Disease-Free Survival
4:09pm
8-K
EX-99.1
gprws8e 8ik5r9c
23 May 24
Other Events
5:41pm
8-K
EX-99.1
m8xnd
15 May 24
Results of Operations and Financial Condition
4:34pm
8-K
EX-99.1
qfjko e22ex3lilbf
5 Apr 24
Other Events
4:33pm
8-K
EX-99.1
o7x3cy99u yn17n3mmn
29 Mar 24
Results of Operations and Financial Condition
8:35am
8-K
EX-99.1
d1eqoodgidrpp 57
17 Jan 24
Other Events
8:35am
8-K
EX-99.1
eiaot79sn
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.1
frg 08fpu23e3w
9 Nov 23
Results of Operations and Financial Condition
4:41pm